News
Tool predicts Alzheimer’s risk years before symptoms appear

A new tool can estimate Alzheimer’s risk years before memory and thinking problems emerge, offering personalised risk scores long before symptoms.
The research builds on decades of data from one of the world’s most comprehensive population-based studies of brain health.
Mayo Clinic researchers developed the prediction model, which found that women have a higher lifetime risk than men of developing dementia and mild cognitive impairment (MCI) — a transitional stage between healthy ageing and dementia that often affects quality of life but still allows people to live independently.
Men and women with the common genetic variant APOE ε4 also have a higher lifetime risk.
Alzheimer’s disease is marked by two key proteins in the brain: amyloid, which forms plaques between nerve cells, and tau, which forms tangles inside nerve cells. Drugs recently approved by the US Food and Drug Administration remove amyloid from the brain and can slow the rate of disease progression for people with MCI or mild dementia.
“What’s exciting now is that we’re looking even earlier — before symptoms begin — to see if we can predict who might be at greatest risk of developing cognitive problems in the future,” said Clifford Jack Jr, radiologist and lead author of the study.
The new prediction model combined several factors, including age, sex, genetic risk associated with APOE genotype, and brain amyloid levels detected on PET scans. Using the data, researchers can calculate an individual’s likelihood of developing MCI or dementia within 10 years or over the predicted lifetime.
Of all the predictors evaluated, brain amyloid levels detected on PET scans had the largest effect on lifetime risk for both MCI and dementia.
“This kind of risk estimate could eventually help people and their doctors decide when to begin therapy or make lifestyle changes that may delay the onset of symptoms. It’s similar to how cholesterol levels help predict heart attack risk,” said Ronald Petersen, neurologist and director of the Mayo Clinic Study of Aging, who is a co-author of the study.
The research draws from the Mayo Clinic Study of Aging, a long-running effort in Olmsted County, Minnesota, that tracks thousands of residents over time. The analysis for this study included data from 5,858 participants.
Unlike most studies, Mayo researchers are able to continue following participants even after they stop actively taking part, using medical record data — ensuring nearly complete information about who develops cognitive decline or dementia.
“This gives us a uniquely accurate picture of how Alzheimer’s unfolds in the community,” said Terry Therneau, who led the statistical analysis and is the senior author of the study. “We found that the incident rate of dementia was two times greater among the people who dropped out of the study than those who continued to participate.”
The study elevates the significance of MCI, which is the stage targeted by current Alzheimer’s drugs that slow but do not stop progression.
While the new tool is currently a research instrument, it represents a step toward more personalised care. Future versions may incorporate blood-based biomarkers, which could make testing more accessible.
The work was supported by the National Institute on Aging, the GHR Foundation, Gates Ventures and the Alexander Family Foundation.
The research is part of a wider effort at Mayo Clinic, called the Precure initiative, focused on developing tools that help clinicians predict and intercept biological processes before they evolve into disease or progress into complex, hard-to-treat conditions.
“Ultimately, our goal is to give people more time — time to plan, to act and to live well before memory problems take hold,” said Dr Petersen.
News
Don’t miss you essential monthly agetech update

Your essential monthly update on agetech’s progress
Welcome to your monthly snapshot of the facts, figures, opinions, trends and challenges shaping the development of agetech.
Our new monthly tracker report aims to provide an concise update for busy agetech professionals on the many factors influencing your work.
Here you will find a concise breakdown of deals, developments and opportunities from the last 30 days; and insight and opinion from leading thinkers in the field.
We hope you find something useful and/or inspiring below – and welcome any feedback about what else you’d like to see included.
News
One in 20 children has high blood pressure, study finds

Rates of high blood pressure in children have almost doubled since 2000, with more than one in 20 now affected, new global research shows.
In 2020, 6.2 per cent of under-19s had high blood pressure, compared with 3.2 per cent in 2000.
High blood pressure, also known as hypertension, now affects 114 million children worldwide, according to an international team including academics from the University of Edinburgh and Zhejiang University in China.
The authors examined data on 443,000 children from 21 countries and found obesity was a substantial driver of the problem.
Nearly 19 per cent of children and adolescents with obesity have high blood pressure, compared with 3 per cent among those with a healthy weight.
In England, one in ten (10.5 per cent) children in the first year of primary school is obese. By the final year, 22.2 per cent are obese, according to the National Child Measurement Programme.
High blood pressure occurs when the force of blood pushing against artery walls is consistently too high, which can damage blood vessels and organs over time.
Co-author Dr Peige Song of Zhejiang University attributed higher rates to unhealthy diets, decreased physical activity and rising childhood obesity.
She said: “The analysis showed that children and adolescents with obesity are nearly eight times more likely to develop hypertension.”
“Parents play a pivotal role in preventing and managing high blood pressure in children.
“Promoting healthy habits, such as a balanced diet rich in fruits, vegetables and whole grains while minimising salt and sugar intake, can substantially reduce the risk of hypertension.”
News
US$100m UK tech entrepreneurs shift focus from real estate to longevity

Whilst running a US$100m-a-year technology business Paul Statham and his team turned their attention to longevity.
Speaking to Agetech World the London-based entrepreneur took up the story: “ I travel extensively and the only way I could keep in touch with my late mother Kathy, who was suffering from dementia, was through the telephone.
“But an hour’s phone call is not the same for someone who wants people around her more of the time, that resonated with me and so we decided to look at the problem and find a solution.”
This led to the foundation of the home-based technology smart speaker Sentai, which provides domestic companionship and assistance for those of advancing years.
Back in 2021 the Sentai team secured £172,568 from quango Innovate UK and Statham and his team have since invested ‘several million pounds’ of their own money bringing Sentai to fruition.
What is Sentai?
Statham elaborated: “Sentai is a smart speaker which uses AI to communicate and support older adults in their daily tasks. It acts as a digital companion as well as a digital assistant.

Paul Statham
“In the assistant space it will provide daily reminders of tasks and appointments, and from the companion perspective, it will engage in conversation.
“The AI technology available now is truly phenomenal; unbelievably clever. It is able to get to know the person it is talking to and truly does become part of their world.
“Sentai is there to support and help people; it doesn’t take over their lives but works as part of their life. It gets to know people and can play games, deliver medical reminders, or, for example, assist with reminder prompts on things such as ensuring their drinking enough water or getting enough exercise.
“As we age, we need more care, but many elderly people are becoming isolated and spending less time with their families, so we came up with the idea of using this technology to help provide additional support.”
What is the potential of Sentai?
Trials of the first Sentai began over the summer with the company looking to launch in January 2026.
It has a number of primary target markets in its sights with the potential to save taxpayers and home care organisations many millions of pounds.
Statham continued: “There’s the retail/consumer market. We’re selling Sentai through the internet, and other primary marketing channels.
“Then there’s the domiciliary care market; companies and organisations who provide home care for people.
“Sentai is a great help to these organisations and they are potentially prime users of the product as it allows them to provide additional hours of coverage with slimmed-down costs.
“In the UK it’s difficult to find domestic care workers, there are not enough as it is, and demand is set to increase. So the domiciliary care market is a massive opportunity and we are really leaning into this.”
Sentai is working with a number of local authorities delivering home care and it is also currently involved in a trial with an NHS Trust in South East which permits two-way communications between a patient and the hospital.
“When patients leave hospital, if they’ve not got a loved one or a family member to stay with them, then they will take a Sentai home. This will allow the hospital to assess their progress and make sure their needs are being met.
“We’ve got various councils piloting Sentai for assisted living in trials which allow the care providers to monitor a patient’s needs with the view of developing Sentai as a concierge service.”
While some trial users have been found to use Sentai more than expected others have been less verbose, and, so, over time the AI speaker is able to familiarise itself with its user’s personalities and deliver ‘concise’ or ‘chatty’ modes depending on individual preferences.
At £29.50 (US’$39) per month, or £294 (US$387) annually for use of the speaker and app, Sentai’s pricing makes the technology relatively accessible.

Keeping families connected
Statham and his team founded their previous company Condeco Software twenty years ago.
It had developed into a leading global player in workspace management and resource scheduling, effectively ensuring the real estate footprint of a company matched its needs.
As the pandemic shifted workspace requirements Condeco’s software made it one of the leading players in its field.
By late 2022, as the company’s annual revenues topped US$100m, it was sold in a private equity deal for an undisclosed sum, with some of this money now being ploughed into Sentai.
Statham added: “We launched our product because we were thinking of our own loved ones and how we wanted to stay in contact with them.
“That is the DNA of the business. We want to keep families connected and keep older adults relevant and help them live independently for longer.
“If we can help with loneliness and companionship, and help connect families to their loved ones, then that will be an unbelievable success.”
Wellness2 months agoExercise may lower dementia risk, study suggests
Technology1 month agoCairns buys AI health app Together by Renee
News2 weeks agoCitrus and grapes may protect against type 2 diabetes
News2 months agoEarly diagnosis can improve ‘dementia journey’, charity says
News3 weeks agoGeneration Lab raises US$11m for ageing diagnostics
News5 days agoSnoring, silence, and the menopause taboo: The hidden health crisis affecting millions
News1 month agoHalf of Brits fear dementia more than any other condition, research finds
News3 weeks agoHospices in England forced to cut beds and staff amid funding crisis





















